Press Release
31 July 2026 08:00:00 CEST

CHANGE IN NUMBER OF SHARES AND VOTES IN MENDUS AB (PUBL)

As previously announced, Mendus AB (publ) ("Mendus") has, pursuant to the authorizations granted by the shareholders at the Annual General Meeting on May 8, 2026, issued a total of 2,200,000 Class C shares in order to facilitate payment of remuneration to board members and bonuses to employees in shares as well as to preserve liquidity. All Class C shares have been converted into ordinary shares.

As a result thereof, the number of shares and votes in Mendus has changed. The issues of shares have resulted in an increase in the number of ordinary shares from 62,584,578 ordinary shares to 64,784,578 ordinary shares.

As of July 31, 2026, the last trading day of the month, there was a total of 64,784,578 ordinary shares and votes in Mendus.

For more information, please contact:
Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com

About Mendus AB (publ)
Mendus is a clinical-stage biopharmaceutical company dedicated to transforming immunotherapy for myeloid malignancies. Based in Sweden and the Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST.
https://www.mendus.com/

This information is information that Mendus AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2026-07-31 08:00 CEST.